Review: angiotension receptor blockers do not differ from ACE inhibitors in chronic heart failure or acute MI
نویسندگان
چکیده
منابع مشابه
ACE inhibitors vs. angiotensin II receptor blockers in acute myocardial infarction and heart failure.
متن کامل
Combination therapy with ACE inhibitors and angiotensin-receptor blockers in heart failure.
Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers have different pharmacologic mechanisms for blocking the effect of the renin-angiotensin-aldosterone system on the cardiovascular system. Pharmacologically, the combination of these drug classes completely blocks the deleterious effect of angiotensin in patients with heart failure. However, clinical trials have not shown...
متن کامل-Blockers in Chronic Heart Failure
Case 1: A 54-year-old man with a history of myocardial infarction (MI) presented with exertional dyspnea. Physical examination was unremarkable. Left ventricular ejection fraction (LVEF) by Doppler echocardiography was 35%, and a stress test was negative for ischemia. The patient was taking aspirin, a statin, and an angiotensin converting enzyme (ACE) inhibitor. He was started on 12.5 mg/d meto...
متن کاملACE inhibitors in heart failure. What dose?
Editorial Ace inhibitors in heart failure. What dose? The role of ACE (angiotensin converting enzyme) inhibitors in the treatment of heart failure is now well established. A large body of published work has demonstrated relief of symptoms, increased exercise performance, a reduction in hospital admissions and superiority to conventional vasodilators. Three large survival studies (CONSENSUS-1,' ...
متن کاملTherapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers in diabetic nephropathy? ACE inhibitors.
Diabetic nephropathy is the number one cause of endstage renal disease in the United States. Blood pressure is most important in delaying the progression of renal disease in persons with diabetes and, agents that block the renin angiotensin system (RAS) should be the primary agents used to achieve blood pressure reduction. There is debate regarding which method of RAS blockade should be used as...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Evidence-Based Medicine
سال: 2005
ISSN: 1356-5524
DOI: 10.1136/ebm.10.3.76